Infinity Pharmaceuticals, Inc., a drug discovery and development company, discovers, develops, and delivers medicines to patients with difficult-to-treat diseases. Its lead product candidate includes IPI-145, an oral inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K) for the treatment of hematologic malignancies. The company is developing DYNAMO, which is in Phase II study to evaluate the safety and efficacy of IPI-145 dosed at 25 mg; DYNAMO+R that is in Phase III randomized study to evaluate IPI-145 dosed at 25 mg in combination with rituximab, a monoclonal antibody treatment; and DUO, which is in randomized Phase III monotherapy study evaluating IPI-145 dosed at 25 mg in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). It is also conducting a Phase Ib trial of IPI-145 in combination with obinutuzumab, a monoclonal antibody treatment in CLL patients; a Phase Ib/II clinical study of IPI-145 in combination with obinutuzumab or rituximab in patients with untreated follicular lymphoma; and an ongoing Phase I dose-escalation study to evaluate the safety, pharmacokinetics, and clinical activity of IPI-145 in patients with advanced hematologic malignancies. The company has collaboration and license agreement with AbbVie Inc. to develop and commercialize IPI-145 in oncology; and development and license agreement with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.